ProMIS Neurosciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- ProMIS Neurosciences ended Q3 2026 with approximately $44.1 million in cash.
- Research and development expenses were approximately $6.7 million, down 32% from $9.8 million a year ago, mainly due to a $3.6 million reduction in direct PMN-310 costs as the PRECISE-AD trial nears completion, partially offset by increased activity in ALS and pipeline programs.
- General and administrative expenses were approximately $1.9 million, roughly flat with $2 million a year ago, while other income rose to about $0.5 million from $0.2 million on higher interest income.
- Net loss for the quarter was $8.2 million, or $0.89 per share, compared with $11.6 million, or $5.93 per share, a year ago.
- For the first 9 months, net loss was roughly $28.1 million, or $3.39 per share, versus $29 million, or $19.58 per share, in 2025.
- At the blinded 6-month interim analysis of 136 patients, ProMIS reported no ARIA-E cases in any APOE genotype, an ARIA-H rate of 4.4% that was all mild and asymptomatic, no drug-related discontinuations, and no treatment-related serious adverse events.
- Blinded pooled interim observations showed plasma PTAP-217 decreased approximately 15% from baseline and CSF MTBR tau-243 decreased approximately 13% from baseline; management said these observations were not a determination of efficacy.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon and welcome to the ProMIS Neurosciences Third Quarter 2026 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following the prepared remarks, we will conduct a question-and-answer session. As a reminder, this call is being recorded. I would now like to turn the call over to Carie Pierce, Vice President of Investor Relations and External Affairs.
Please go ahead. Thank you, operator, and good afternoon, everyone.
Earlier today, ProMIS issued a press release announcing our financial results for the third quarter ended September 30, 2026, and provided a corporate update. The press release is available on the Investor section of our website and on our quarterly report on Form 10-Q and has been filed with the SEC and on SEDAR+. Joining me on today's call are Neil Warma, our President and Chief Executive Officer, who will deliver our prepared remarks, and Dr. Larry Altstiel, our Chief Medical Officer, who will be available during the Q&A session. Before we begin, I would like to remind everyone that today's call will include forward-looking statements with the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws.
These include, among others, statements regarding our clinical development plan and timelines for PMN310 and other product candidates, the interpretation and significance of the blinded interim data from our PRECISE-AD trial, our expectations regarding future clinical results, including the timing of top-line data, our financial position and cash runway, and our overall business strategy. These statements are based on management's current expectations and are subject to risks and uncertainties that could differ from actual results materially, including the risk that early or interim results may not be indicative of final or top-line results. Please refer to the Risk Factor section in our most annual report on Form 10-K and our subsequent filings with the SEC, including our quarterly report on Form 10-Q for the quarter ended September 30, 2026.
These statements speak as of today, November 12, 2026, and we undertake no obligation to update them except as required by law. With that, I will turn the call over to Neil.
Thank you, Carie. Good afternoon, everybody, and thank you for joining. ProMIS is entering probably the most important period in its history. Our phase I-B study, PRECISE-AD, in Alzheimer's disease is nearing completion. All patient visits are expected to conclude this quarter, and unblinded 12-month top-line data remain on track for the first quarter of 2027. Today, I want to focus on four things: why recent events in the field sharpen rather than weaken the case for PMN310, the strength of the interim data from July that we have seen in our PRECISE-AD trial, how we will judge the top-line results coming shortly, and how we are positioned both strategically and financially to move efficiently once we have the data. First, I want to directly address the phase II results reported two weeks ago by another company developing an antibody described as oligomer selective.
That trial did not meet its primary or secondary endpoints at 18 months. We have looked closely at the limited data that were disclosed, and two key findings really stand out to us. First, that the antibody produced statistically significant reductions in amyloid plaque on PET at both doses. Second, approximately 10% of treated patients developed ARIA-E, or brain swelling. In our view, both of those findings indicate meaningful engagement of plaque and fibrillar amyloid, not selective targeting of oligomers. That matters. A molecule that clears plaque and causes ARIA is behaving much like the existing plaque-directed drugs. So in our view, that trial did not test the oligomer hypothesis. Selectivity is not a label. It has to be demonstrated both at the bench and in patients. This is precisely where we believe PMN310 is different, and the data we have to date support that view.
The field still needs a clinical test of oligomer-selective targeting. We believe PRECISE-AD will be that test. Let me explain a little what sets PMN310 apart. PMN310, our lead candidate, our lead antibody, was built around one hypothesis, that toxic A-beta oligomers drive neurodegeneration in Alzheimer's disease, and that selective neutralizing and clearing them can deliver benefit without the safety burden of plaque-directed therapies. Three key features set PMN310 apart. Number one, selectivity. In head-to-head preclinical studies, PMN310 was the only antibody tested that bound toxic oligomers while avoiding monomers, avoiding fibrils, and avoiding plaque. Other antibodies include those described as oligomer selective, consistently showed binding to plaque. Additionally, the interim results from our phase I-B study presented last July, or this past July, have reaffirmed our confidence in PMN310's selective profile. Number two is design. Like the two approved antibodies, PMN310 is built on an IgG1 backbone to engage microglia and actively clear toxic oligomers from the brain.
We deliberately chose both neutralization and clearance. Number three is safety. By avoiding plaque, PMN310 is designed to reduce the risk of ARIA, which is still the single greatest barrier to the broader use of anti-amyloid therapy. At our six-month interim analysis, PRECISE-AD showed no ARIA-E, zero cases of ARIA-E in any APOE genotype. That's meaningful because with the approved antibodies, most ARIA occurs within the first six months of treatment. Though the interim read, to be clear, is not definitive, but it gives us real confidence going forward. The burden of ARIA goes beyond the brain swelling and bleeding it causes. To monitor for it, patients on the approved therapies must undergo as many as six MRI scans in their first year of treatment.
Keep in mind, these are cognitively impaired patients, and every scan is a real physical and financial burden on them, their caregivers, and the healthcare system. Our goal with PMN310 is to reduce the incidence of ARIA, and with it, dramatically reduce the need for repeated MRI monitoring. Should PMN310 deliver ARIA rates at or near placebo, with efficacy at least as comparable to existing therapies, we believe it could become a leading treatment for early Alzheimer's disease, and even open the door to preclinical asymptomatic patients where safety is absolutely paramount. Just as a reminder to the audience, the blinded six-month interim analysis of 136 patients, randomized 3:1 active to placebo, that we reported July 28th of this year, gave us an encouraging early read. There were no ARIA-E cases in any APOE genotype as of our cutoff date.
ARIA-H, a rate of 4.4%, all mild and asymptomatic, very much in line with placebo rates. There were no drug-related discontinuations, no treatment-related serious adverse events. On the target engagement potential drug effect side, we demonstrated pooled plasma p-tau217 decreased approximately 15% from baseline, and CSF MTBR-tau243 decreased approximately 13% from baseline. Remember, these are blinded pooled observations and not a determination of efficacy, but they are consistent with target engagement, and the safety profile is what we would expect from a true oligomer-selective antibody. Although no head-to-head studies have been conducted, our interim safety profile really stands in clear contrast to the ARIA-E rates seen in the recent competitor trial, and also with approved therapies. Let me turn to what we would consider a win when the top-line data read out in Q1 next year.
Every Alzheimer's therapy is ultimately judged on its balance of benefit and risk, as weighed by the FDA, by prescribing physicians, by patients, and their families. Today, that balance is a difficult one. The approved antibodies offer a modest slowing of decline at the cost of ARIA risk and an intensive MRI schedule. Our goal is to shift that balance decisively. PMN310 is designed to do that by lowering the risk side of the balance while preserving the benefit. Efficacy comparable to the approved therapies with a clear safety advantage would shift it meaningfully. Any efficacy above what we see with the marketed drugs would shift it even further. At top line, we will evaluate the totality of the data against that goal, really looking at four things. With respect to safety, we're looking for ARIA, drug-related adverse events, event rates approaching or comparable to placebo rates.
Clinical efficacy, we want to see a directional slowing of decline on either the iADRS or CDR Sum of Boxes versus placebo, so similar to approved therapies at the 12-months time point. Biomarkers, we would like to see changes that align with PMN310's oligomer-targeted mechanism, so directional trends in line with our oligomer selectivity mechanism of action. With respect to mechanism of action, we would like to show direct changes in oligomer levels following treatment with PMN310. If PRECISE-AD, if our clinical trial demonstrates a material shift in the benefit-risk profile, we believe it would be a significant value-creating event for ProMIS and a very meaningful step forward for patients. I want to take a minute now just to talk about how we are preparing for what comes next. We're not waiting. We're not sitting and waiting for top-line data to come to plan the next phase.
With fast-track designation already in hand, we intend to request a meeting with FDA after the full set of data is analyzed. In parallel, we're developing a subQ formulation of PMN310 and preparing for a potential registration study, which we could envision beginning towards the end of 2027, subject to FDA feedback, of course. We have also strengthened the team for that next phase. As we reported on October 5, Dr. Ivana Rubino has joined the ProMIS team as Chief Commercial Officer. Ivana brings more than 15 years of global neuroscience and Alzheimer's leadership from senior roles at Biogen and at Roche, and she will help shape our regulatory, late-stage development, and commercial strategy. Attracting someone of Ivana's caliber, I think, speaks volumes to the potential of PMN310 and our overall platform.
On that note, while we have a strong pipeline of selective antibodies for other serious neurodegenerative diseases with high unmet medical need, and this includes ALS, Parkinson's disease, dementia with Lewy bodies, I have focused today's call on our commitment to the Alzheimer's patients and their caregivers, and really around the enthusiasm we have for PMN310 and the upcoming data release. Before we kind of jump into a few questions and answers, I just want to turn briefly to our financial results for the quarter. We ended Q3 with approximately $44.1 million in cash, which we expect to fund operations through 2027, well beyond the PRECISE-AD readout. You can find full details of our financials in our press release and our Form 10-Q that was filed today.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
